Risks and Side Effects of Hormone Therapy in Women: A Comparison by Type and Timing

Why the Risk Profile Depends on Which Hormone Therapy You Mean

Hormone therapy in women is not one treatment. It is a family of regimens that differ in the hormones used, the route of delivery, the dose, the age at which it starts, and how long it continues. A woman taking estrogen alone after a hysterectomy is in a different risk category from a woman taking estrogen plus a progestogen with an intact uterus, and both differ from someone using a low-dose vaginal product for genitourinary symptoms. Comparisons only make sense when the specific regimen is named.

The distinction that matters most in the medical literature is between systemic therapy, which travels through the bloodstream and affects the whole body, and local therapy, which acts mainly where it is applied. Systemic products include oral tablets, transdermal patches, gels, sprays and injections. Local products include vaginal creams, tablets and rings. Systemic therapy carries the risks that dominate headlines; local low-dose therapy largely does not, because absorption into the bloodstream is minimal.

A second distinction is between combined therapy (estrogen plus a progestogen) and estrogen-only therapy. Progestogens are added to protect the uterine lining in women who still have a uterus, because unopposed estrogen raises the risk of endometrial cancer. That protective benefit comes with its own trade-offs, and the type of progestogen, whether a natural progesterone or a synthetic progestin, changes some of the risk estimates. Any discussion of side effects has to specify which of these is being discussed.

This article compares risks across these categories. It is general information, not medical advice. Whether hormone therapy is appropriate for an individual depends on her history, symptoms, family risk factors and preferences, and that decision belongs with a clinician who knows her case.

Cardiovascular and Clotting Risks: The Largest Differences Between Regimens

Venous thromboembolism, meaning deep vein thrombosis and pulmonary embolism, is the risk most consistently linked to oral estrogen. The risk is elevated compared with not taking hormone therapy, and it appears higher with oral than with transdermal delivery. This route difference is one of the clearest findings in the field: estrogen absorbed through the skin avoids the first pass through the liver, which is where many clotting factors are produced. For a woman who already has a personal or strong family history of clots, that distinction can be decisive.

Stroke risk follows a similar pattern. Oral combined therapy has been associated with an increased risk of ischemic stroke, and the increase appears to be dose-related and to persist for some years after stopping. Transdermal preparations have not shown the same signal in observational data, though the evidence is less definitive than for clotting. The comparison matters because a woman weighing symptom relief against stroke risk may reasonably prefer a patch or gel over a tablet if her clinician agrees.

Coronary heart disease risk is more complicated and depends heavily on age and time since menopause. In women who start hormone therapy many years after menopause, particularly in their sixties or seventies, the data point toward increased coronary risk. In women who start within about ten years of menopause, generally in their fifties, the picture is closer to neutral or possibly favorable. This age-dependent pattern is why the same drug can appear harmful in one study and harmless in another.

Blood pressure can rise modestly with oral estrogen in some women, though the effect is usually small. Anyone starting systemic therapy typically has blood pressure monitored, and a meaningful rise is a reason to reassess the regimen rather than to ignore it.

Cancer Risk: Breast, Endometrial and the Role of Progestogens

Breast cancer risk is the adverse effect women ask about most. Combined estrogen-progestogen therapy is associated with an increased risk of breast cancer, and the increase appears to grow with duration of use and to decline after stopping. Estrogen-only therapy has shown a smaller or, in some analyses, no clear increase. The absolute numbers matter here: the increase in risk for an individual woman over a few years of use is generally small, even though the relative increase reported in large studies sounds alarming. A clinician can translate that into a personal estimate.

Endometrial cancer risk moves in the opposite direction depending on the regimen. Estrogen taken alone by a woman who still has a uterus raises the risk of endometrial cancer, which is why a progestogen is prescribed alongside it. Adequate progestogen exposure, whether continuous or cyclical, brings that risk back down toward the level seen in women not taking hormone therapy. This is a case where the comparison between regimens is stark: the same estrogen that is protective in one combination is risky in another.

Ovarian cancer has been linked to hormone therapy in some studies, with a modest increase in risk that appears to fall after use stops. The evidence is less consistent than for breast or endometrial cancer, and different analyses have reached somewhat different conclusions. Colorectal cancer, by contrast, has appeared less common among hormone therapy users in some large trials, though screening recommendations do not change because of it.

These are population-level patterns, not predictions about any one woman. Personal risk is shaped by genetics, reproductive history, body weight, alcohol use and other factors that can outweigh the effect of hormone therapy itself.

Common Side Effects That Affect Daily Life

Beyond the serious risks, many women stop hormone therapy because of side effects that are uncomfortable rather than dangerous. These are common enough that they are worth anticipating, and they often improve after the first few weeks or can be reduced by adjusting the dose or route. The comparison between oral and transdermal delivery shows up here too: some side effects are more frequent with tablets because of how the liver processes oral estrogen.

The list below covers effects reported across systemic regimens. Not every woman experiences them, and the pattern differs between combined and estrogen-only therapy.

Vaginal bleeding is the side effect that most often prompts a phone call to a clinician. Irregular bleeding is common in the first months of combined therapy, especially with cyclical regimens. Any bleeding that is new, heavy, prolonged or occurs after menopause should be evaluated rather than assumed to be normal, because it can be a sign of a problem in the uterine lining.

• Breast tenderness and swelling, often worst in the first weeks
• Nausea, particularly with oral tablets taken on an empty stomach
• Headaches or migraines, which may worsen in women who already have them
• Mood changes, irritability or anxiety, sometimes linked to the progestogen component
• Bloating, fluid retention and temporary weight change
• Spotting or breakthrough bleeding, especially early in treatment
• Leg cramps and, less often, gallbladder problems with oral estrogen

How Route, Dose and Timing Change the Comparison

The same hormone can behave differently depending on how it enters the body. Oral estrogen passes through the liver before reaching the general circulation, which amplifies its effect on clotting factors, triglycerides and some inflammatory markers. Transdermal estrogen, delivered by patch, gel or spray, bypasses that first pass. For a woman whose main concern is clot risk, this is often the single most useful comparison in the whole field.

Dose matters as well. Standard-dose systemic therapy carries the risk estimates reported in the large trials. Lower-dose systemic preparations and ultra-low-dose vaginal products sit at a different point on the scale. Low-dose vaginal estrogen, used for dryness, burning and recurrent urinary symptoms, has not been shown to raise the risks associated with systemic therapy, because very little reaches the bloodstream. That makes it a genuinely different option rather than a smaller version of the same thing.

Timing relative to menopause changes the comparison again. Starting systemic therapy within roughly ten years of menopause, typically in the fifties, appears to carry a more favorable cardiovascular profile than starting in the sixties or later. Duration also matters: risk estimates for breast cancer and stroke tend to rise with years of use, which is why many clinicians favor the lowest effective dose for the shortest time that manages symptoms, with periodic review rather than automatic renewal.

Progestogen choice adds another variable. Micronized progesterone has been associated with a somewhat different metabolic and breast-related profile than some synthetic progestins in observational research, though the evidence is not settled enough to make blanket claims. This is a question to raise with a prescriber rather than to resolve from general reading.

Weighing Symptom Relief Against Adverse Effects

Hormone therapy remains the most effective treatment for vasomotor symptoms such as hot flashes and night sweats, and for genitourinary symptoms of menopause. That effectiveness is the reason the risks are worth discussing rather than simply avoiding. The comparison a woman actually faces is not between hormone therapy and nothing; it is between hormone therapy and the alternatives, which include lifestyle measures, non-hormonal prescription medications, and approaches such as homeopathy that some women choose for symptom support.

The evidence base for homeopathic treatment of menopausal symptoms is limited, and reviews have generally not found effects clearly distinguishable from placebo. That does not mean individual women get no benefit, but it does mean the risk-benefit comparison is not symmetric: homeopathic remedies are not associated with the clotting, stroke or cancer risks described above, while hormone therapy has documented effectiveness that homeopathy has not demonstrated to the same standard. Neither point cancels the other.

What makes the decision tractable is personalization. A woman with a history of breast cancer, a prior blood clot, unexplained vaginal bleeding, active liver disease or a known thrombophilia is generally advised against systemic hormone therapy, and that advice is fairly firm. A healthy woman in her early fifties with distressing hot flashes and no contraindications faces a much more open comparison, where route, dose and duration can be tuned to reduce risk.

Anyone weighing these options should bring her full medical and family history to a clinician, ask specifically about transdermal versus oral delivery, ask how long treatment would continue and how it would be reviewed, and ask what the absolute, not relative, change in her personal risk would be. Those four questions turn a frightening statistic into a decision she can actually make.